Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | PLK1 | P53350 | 2/20 | 0.46 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.46 |
| ▸ | PRKX | P51817 | 1/20 | 0.46 |
| ▸ | NEK4 | P51957 | 1/20 | 0.46 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.46 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7689885 | 1.00 | ALDH1A1 (0.57) | ALDH1A1KMT2AMEN1POLBMAPKAPK2 | |
| SCHEMBL7011839 | 0.80 | KMT2A (0.62) | ALDH1A1KMT2AMEN1POLBCYP3A4 | |
| SCHEMBL7014918 | 0.80 | PLK1 (0.50) | ALDH1A1KMT2AMEN1POLBMAPKAPK2 | |
| SCHEMBL15004002 | 0.74 | ALDH1A1 (1.00) | ALDH1A1KMT2AMEN1POLBEGFR | |
| SCHEMBL15137443 | 0.74 | ALDH1A1 (1.00) | ALDH1A1KMT2AMEN1POLBEGFR | |
| SCHEMBL3172125 | 0.74 | ALDH1A1 (1.00) | ALDH1A1KMT2AMEN1POLBEGFR | |
| SCHEMBL7534311 | 0.72 | MEN1 (0.59) | ALDH1A1KMT2AMEN1POLBMAPK1 | |
| SCHEMBL7011665 | 0.72 | MEN1 (0.62) | ALDH1A1KMT2AMEN1POLBCYP3A4 | |
| SCHEMBL10967156 | 0.71 | LMNA (0.62) | ALDH1A1KMT2AMEN1POLBCYP2C9 | |
| SCHEMBL11221573 | 0.71 | ALDH1A1 (0.86) | ALDH1A1KMT2AMEN1POLBACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003529532-A | — | — | 2003-10-07 | — | — | JP | claimed |
| US-20020177613-A1 | 4-substituted-3-substituted-amino-cyclobut-3-ene-1,2-diones and analogs thereof as novel potassium channel openers | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-11-28 | — | — | US | claimed |
| US-6376555-B1 | MUSCLE RELAXANTS | AMERICAN HOME PRODUCTS CORPORATION | 2002-04-23 | — | — | US | claimed |
| EP-1135365-A1 | 4-3-SUBSTITUTED-AMINO-CYCLOBUT-3-ENE-1,2-DIONES AND USE FOR INFLUENCING SMOOTH MUSCLE CONTRACTION | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-09-26 | — | — | EP | claimed |
| WO-2000034230-A1 | 4-3-SUBSTITUTED-AMINO-CYCLOBUT-3-ENE-1,2-DIONES AND USE FOR INFLUENCING SMOOTH MUSCLE CONTRACTION | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | claimed |
| US-20020177613-A1 | 4-substituted-3-substituted-amino-cyclobut-3-ene-1,2-diones and analogs thereof as novel potassium channel openers | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-11-28 | — | — | US | disclosed |
| US-6465523-B1 | TREATMENT OF SMOOTH MUSCLE CONTRACTION DISORDERS SUCH AS URINARY INCONTINENCE, ASTHMA, PREMATURE LABOR, IRRITABLE BOWEL SYNDROME, CONGESTIVE HEART FAILURE, ANGINA, CEREBRAL VASCULAR DISEASE | AMERICAN HOME PRODUCTS | 2002-10-15 | — | — | US | disclosed |
| US-6462059-B1 | TREATMENT OF DISORDERS ASSOCIATED WITH SMOOTH MUSCLE CONTRACTION; URINARY INCONTINENCE, ASTHMA, PREMATURE LABOR, IRRITABLE BOWEL SYNDROME, CONGESTIVE HEART FAILURE, ANGINA, AND CEREBRAL VASCULAR DISEASE | AMERICAN HOME PRODUCTS | 2002-10-08 | — | — | US | disclosed |
| US-6376555-B1 | MUSCLE RELAXANTS | AMERICAN HOME PRODUCTS CORPORATION | 2002-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177613-A1 | 4-substituted-3-substituted-amino-cyclobut-3-ene-1,2-diones and analogs thereof as novel potassium channel openers | KCNN3, KCNJ2, KCNE1 | ALDH1A1 1434/4885KMT2A 584/4885MEN1 2365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.